Treatment successes with talc pleurodesis at patients (pts.) with recurrent malignant pleural effusions (PE) Source: Eur Respir J 2002; 20: Suppl. 38, 438s Year: 2002
Efficacy of pleurodesis for malignant pleural effusions in breast cancer patients Source: Eur Respir J 2011; 38: 1425-1430 Year: 2011
Prognostic factors in patients with malignant pleural effusion undergoing thoracoscopy Source: Annual Congress 2011 - From outside to inside: access to the pleura Year: 2011
Malignant pleural effusions Source: ISSN=1025-448x, ISBN=1-904097-25-1, page=177 Year: 2002
Therapeutic local procedures: pleurodesis Source: ISSN=1025-448x, ISBN=1-904097-25-1, page=311 Year: 2002
Pleurodesis success rate for malignant pleural effusions - talc slurry vs. poudrage Source: International Congress 2016 – Malignant pleural disease: diagnosis and management Year: 2016
Talc pleurodesis in malignant pleural effusions: A 5-year experience Source: Annual Congress 2012 - Medical access to the pleura Year: 2012
Thoracoscopic talc poudrage (TTP) in malignant (M) pleural effusion (PE): when to perform it? Source: International Congress 2019 – Interventional pulmonology: current pleural practice Year: 2019
Efficacy of talc slurry pleurodesis in malignant pleural effusions Source: International Congress 2015 – Malignant pleural effusions and mesothelioma Year: 2015
Thoracoscopic talc pleurodesis‘(TTP) safety and clinical efficacy in malignant pleural effusions (MPE) Source: Annual Congress 2010 - 100 years of thoracoscopy: still room for improvement? Year: 2010
Hemorrhagic malignant pleural effusion: Diagnosis, survival rate, and response to talc pleurodesis Source: International Congress 2014 – Diagnosis of pleural effusions and mediastinal adenopathies Year: 2014
CD8+ lymphocyte subpopulations in pleural fluid are associated with longer survival in patients with malignant pleural effusion (MPE) submitted to thoracoscopic talc pleurodesis Source: Eur Respir J 2002; 20: Suppl. 38, 70s Year: 2002
Efficacy of talc pleurodesis in patients with malignant pleural effusions Source: Annual Congress 2011 - Molecular markers: diagnosis and management of malignant pleural effusions Year: 2011
Long-term outcome of patients with non-specific pleuritis on thoracoscopic or ultrasound-guided pleural biopsies Source: International Congress 2016 – Mesothelioma and pleural disease: from the bench to the bedside Year: 2016
Histology, performance status and lymphopenia are factors of survival in patients undergoing thoracoscopy for malignant pleural effusion Source: Annual Congress 2009 - Trends in bronchoscopy Year: 2009
Diagnostic thoracoscopy in suspected malignant disease of the pleura: Pleural nodularity justifies talc poudrage Source: Annual Congress 2011 - Molecular markers: diagnosis and management of malignant pleural effusions Year: 2011
Predictors of successful pleurodesis for patients with malignant pleural effusions Source: Eur Respir J 2004; 24: Suppl. 48, 493s Year: 2004
Outcomes of bedside talc slurry pleurodesis for malignant pleural effusions: A retrospective analysis Source: Annual Congress 2013 –Diagnosis and management of pleural and mediastinal diseases Year: 2013
Efficacy of thoracoscopic talc poudrage pleurodesis and predictive factors for its success in malignant pleural effusions Source: Eur Respir J 2005; 26: Suppl. 49, 72s Year: 2005
Can serum (CRP) levels estimate the outome of talc pleurodesis in malignant pleural effusions? Source: Annual Congress 2012 - Diagnosis and biology of malignant pleural effusions Year: 2012